Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol dose-reduction and withdrawal study for maintenance of remission in active axial spondyloarthritis
2015-000339-34Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in axial spondyloarthritis (axSpA) (4 arms), sponsored by UCB. Primary endpoint: Percentage of subjects in Part B who do not experience a flare. Started Jun 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2015-000339-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000339-34.